Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder

Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial